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ABSTRACT 
 
Aims: Melissa officinalis (Mo) and Lavandula angustifolia (La) essential oils and their 
major constituents ((E) - caryophyllene, caryophyllene oxide, geranyl acetate, linalool, 
nerol, Oct-1-en-3-ol, 3-Octanone, myrcene, allo-ocimene, p-cymene and α- terpineol) 
assessed by GC-MS) which are shared by these two essential oils were probed in an 
attempt to identify the GABAAR ligand(s). 
Study Design: [35S] t-butylbicyclophosphorothionate (TBPS) radioligand binding assay to 
GABAA receptors. In vitro neuronal viability assay. 
Place and Duration of Study: School of Biological and Biomedical Sciences, Durham 
University, United Kingdom (December 2012 and January 2013). 
Results: One of the major component (s) of (Mo), trans-ocimene, inhibited [35S] (TBPS) 
binding to native GABAA receptors in a concentration-dependent manner with an apparent 
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IC50 of 40M. 
Concentrations (0.001 mg/ml) of whole (Mo) were shown to display modest beneficial 
effects upon neuronal viability while at a higher concentration (0.1 mg/ml) of (Mo) and (La) 
oils induced a neurotoxicity effect. 
Conclusion: These data provide the first evidence that allo-ocimene is an neuroactive 
GABAA R inhibitory component found in both (Mo) and (La), and represents a novel 
GABAA  receptor channel chemotype derived from a natural product. 
 
 
Keywords: Melissa officinalis (Mo); Lavandula angustofolia (La); [35S]-t-
butylbicyclophosphorothionate ([35S] TBPS); gamma-aminobutyric acid (GABA)A 
receptor. 
 
1. INTRODUCTION  
 
In the last 20 years, there has been a revival of interest in natural products and medicinal 
plants. Melissa officinalis, Lavandula angustifolia, Ginkgo biloba, Salvia lavandulae folia and 
Rosmarinas officinalis have been widely used in aromatherapy. This has involved the use of 
the whole plants, parts of plants, or the pure essential oils (EOs) with aims to treat health 
problems. Alzheimer’s disease (AD) is a neurological disorder characterised by a 
progressive impairment of cognition and behavioural mood deficits that leads to a person 
unable to perform even simple daily life activities [1-6]. The management of behavioural and 
psychological symptoms of dementia (BPSD) such as agitation, psychosis and mood 
disorders remains a major problem for people with AD in clinical care [7,8]. BPSD develop in 
more than 90% of people with dementia over a five year period. Melissa officinalis (lemon 
balm) and Lavandula augustifolia (lavender), singly or in combination are the most well-
known (EOs) that have been used for the treatment of agitation in controlled clinical trials. 
These (EOs) demonstrated significant effects in reduction of agitation, wandering, insomnia 
and social withdrawal [9,10,3]. There is mounting evidence that links BPSD to specific 
alteration in neurochemistry, which may underpin the basis of pharmacological manipulation. 
Dementia is associated with dysfunction in multiple neurotransmitter systems. Although the 
most well studied neuronal system dysfunction lies in the cholinergic system, there is also 
evidence supporting serotonergic, noradrenergic, dopaminergic and GABA systems [11]. 
These neurotransmitters are known to regulate behaviours and are amenable to 
pharmacological intervention. Several important classes of clinically used drugs such as 
benzodiazepines, barbiturates and anesthetics, have actions which are mediated by 
allosteric interaction at the GABAA receptor [12-14]. The great molecular diversity of the 
multi-subunit hetero-oligomeric GABAA receptor provides opportunities to develop novel 
drugs, for example for anxiety, sleep disorders, alcoholism and epilepsy by establishing the 
relevant molecular targets for receptor subtype specific action [15-17]. In this present report, 
we attempted to identify the component that probably accounts for GABAA receptor binding 
properties of the Melissa and Lavender essential oils [18,19]. 
 
2. MATERIALS AND METHOD  
 
2.1 Chemicals and Herb Samples 
 
The sample of (Mo) was obtained from Fytosan (France) and the components of (Mo) 
essential oil were either obtained from Sigma (Poole, UK) or Acros (Loughborough, UK). 
This batch of (Mo) was selected and validated based on previous pharmacological and 
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chemical studies using batches from four common suppliers (Baldwins (London, UK), 
Pranarom (Lille, France), Quinessence (Coalville, UK), Fytosan (Die, France); the 
composition correlates with the natural products Herbal Pharmacopoeia standards and was 
confirmed to be stable throughout the research programme (Dr Melanie-Jayne Howes, 
Jodrell Laboratory, Kew Gardens). Furthermore, a batch was selected and used in a parallel 
clinical trial in late-stage of Alzheimer’s disease patients [18,19]. The GC-MS profile carried 
out at the Royal Botanic Garden at Kew (London), displayed no major changes in (Mo) 
composition following long-term storage (18 months) at 4°C in the dark (composition 
reported previously in [18,19]). Dilutions of essential oil stocks or components were 
performed fresh on the day of assay. [35S]-t-butylbicyclophosphorothionate (TBPS; specific 
activity 80 Ci mmol-1) was from Perkin Elmer Life Science (Waltham, MA, USA.  Essential 
oil stock solutions or constituents were prepared in dimethylsulphoxide (DMSO) first then in 
the appropriate assay buffers. The solvents had no effect on radiolig and binding assays at 
concentrations below 0.1% (v/v) ethanol or DMSO [15]. 
 
2.2 Radiolig and Binding Assay 
 
2.2.1 Tissue preparation and processing 
 
Animal treatment and husbandry were in accordance with approved use of animals in 
scientific procedures regulated by the Animals (Scientific Procedures) Act 1986, UK. Brains 
from adult male Wistar rats (200-300g) were sacrificed humanely by using a standard 
Schedule 1 procedure. The brains were removed rapidly, and the required tissue (forebrain) 
dissected immediately and kept cool on ice. The tissue was then homogenised using a 
Dounce glass/glass homogeniser in ice–cold homogenisation buffer containing: 50mM Tris 
HCl, pH 7.4, containing 5mM EDTA, 5mM EGTA and 320 mM sucrose. The homogenate 
was then centrifuged at 1000xg for 10min at 4°C.The supernatant was stored in ice and the 
pellet re-homogenised in ice-cold buffer, centrifuged at 1000g for 10min at 4°C.The 
supernatants from the first and second centrifugation steps were pooled and centrifuged at 
15,000xg for 30min at 4°C.The supernatant was discarded and the pellet re-dissolved in               
50mM Tris containing 5mM EDTA and 5mM EGTA, processed using a five-step freeze–thaw 
protocol [15], frozen and stored at -20°C. The protein concentration was then determined 
using the Lowry assay [17] using bovine serum albumin as the standard protein. 
 
2.2.2 Radiolig and binding assay 
 
[35S] TBPS binding were determined as described by [15] using well-washed rat forebrain 
membranes. In order to measure [35S] TBPS binding, membranes were incubated in 50mM 
Tris buffer containing 0.2MNaCl, pH 7.4; using approximately 20nM [35S] TBPS for 90 min at 
25°C with a range of test concentrations of (Mo) constituents (0.001-0.1mg/ml). Non-specific 
binding was defined in the presence of 10µM picrotoxinin. 
 
2.3 Mixed Cortical Cultures 
 
Mixed cortical were prepared as previously described [16]. Briefly, cultures were prepared 
from 16- to 18-day-old rat embryos (Sprague-Dawley strain) in B27neurobasal media and 
plated on poly-D-lysine coated 24-well plates at a cell density of 3000cells/mm2. The cells 
were maintained by adding fresh neurobasal media at DIV3 (Days In vitro 3) and DIV7 (Days 
In vitro 7). 
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2.4 Oil Experiment 
 
On DIV7, Sunflower oil (Control oil) or Melissa oil (0.001 or 0.01mg/ml both dissolved in 
DMSO<0.01%v/v) in fresh media was added to neuronal cultures (4wells) for 24h. The 
emulsifying agent which was used is DMSO, which showed no effect in control experiments 
and, therefore, this justified that it is the (Mo) that is having the effect on the neuronal 
cultures and not the emulsifying agent. Furthermore, the sham treatment was performed with 
Sunflower oil in the presence of DMSO. 
 
2.5 Statistical Analysis 
 
Data were expressed as the mean±SEM and analysed using one-way of variance and 
Student’s t-test as appropriate using Prism 4 software (Graph Pad, CA.USA). P values 
below 0.05 were considered significant. 
 
3. RESULTS AND DISCUSSION 
 
3.1  Effects of Melissa Oil constituents on the Channel Binding Site of the 
GABAA receptor labelled by [35S] TBPS 
 
The effects of the twelve major oil constituents, common to both Melissa officinalis and 
Lavandula angustifolia essential oils, were probed on the channel site of GABAA receptor. 
[35S] TBPS binding studies were carried out to a well washed adult forebrain, using three 
different concentrations (0.001,0.01,0.1mg/ml) of the constituents (linalool, limonene, (E)-
caryophyllene, caryophyllene oxide, nerol, p-cymene, geranyl acetate, 3- octanone, oct-1-
en-3-ol, myrcene, ocimene and α-terpineol). The inhibition of [35S] TBPS binding by 
increasing concentrations of the oil constituents was dose-dependent, attaining 50% 
inhibition between 0.01-0.1mg/ml for many of the constituents Fig. 1, Table 1. 
 
3.2 Effects of Melissa Essential oil (Mo) on Neuronal Viability  
 
Previous studies [18,19] suggest that (Mo) may display neuro protective properties, via a 
sodium channel blockade mechanism. This potential was investigated using a primary 
neuronal culture system as described in [16]. At 0.001mg/ml, (Mo) elicited a modest 
preconditioning effect (increased viability versus saline control) (approx.10%, p<0.05), but at 
>0.01mg/ml (Mo) was shown to cause neurotoxicity (approx. 20%, p<0.01) Fig.2. the latter 
which is consistent with the GABAA receptor inhibitory pharmacology Fig.1. and [18]. 
 
In previous studies, both Melissa and Lavender essential oils have been shown to possess 
GABAAR inhibitory activity using [35S] TBPS binding and electrophysiological methodologies 
[18,19]. Results presented in this study show that, in concentration dependent manner, most 
of the (Mo) constituents demonstrated only modest antagonistic effects on [35S] TBPS 
binding with the exception of trans-ocimene Fig. 1. Which inhibited [35S] TBPS binding at 
0.01mg/ml compared to the control. In fact, trans-ocimene inhibited [35S] TBPS binding with 
an apparent IC50 of 0.006 mg/ml (40µM) Table 1, while nerol and linalool demonstrated 
inhibition only at the highest concentration tested, which was 0.1 mg/ml. Concentrations 
(0.001 mg/ml) of whole (Mo) were shown to display modest beneficial effects upon neuronal 
viability, consistent with our previous studies indicating  effects of both oils upon voltage-
gated sodium channels at low concentrations [18,19,20 and unpublished studies], while at a 
higher concentration (0.1mg/ml) of (Mo) Fig. 2 and La (not shown) induced a neurotoxicity 
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effect. Interestingly, this study has revealed a new GABAA receptor ligand, namely trans-
ocimene.  
 
Table 1. Effects of Melissa and Lavender oil common constituents on the channel 
binding site of the GABAAR labelled by [35S] TBPS 
 
Chemical name            Structure               IC50(mg/ml)   IC50(µM) 
Melissa essential oil  0.019 - 
Geranyl acetate 
 
17.0 87200 
(E)-Caryophyllene 
 
0.028 138 
Caryophyllene oxide 
 
0.584 2650 
Limonene 
 
0.256 1878 
Myrcene 
 
6.840 50205 
Ocimene* 
 
0.006 40 
p-Cymene 
 
0.035 262 
3-Octanone 
 
0.038 299 
Linalool 
 
0.900 5837 
Nerol 
 
0.079 513 
Oct-1-en-3-ol 
 
1.140 8891 
α-Terpineol 
OH
 
0.211 1369 
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Fig. 1. The effects of the shared Melissa and Lavender essential oil constituents on 
[35S] TBPS binding to well-washed rat forebrain membranes. Data are expressed as 
the mean±SD from at least three separate experiments 
 
Although the (Mo) constituent(s) demonstrated antagonistic effects, potential therapeutic 
effects of (Mo) and its constituent(s) need to be investigated further. Bilobalide, a single 
natural product sesquiterpene trilactone derived from Ginkgo biloba, which has been used 
for the treatment of AD displayed a similar inhibitory effect on GABAA receptor as seen 
herein, and also neuroprotective effects, presumably through other mechanisms [21], again 
similar to that observed for Melissa essential oil. Electrophysiological studies have shown 
that (Mo) depress membrane excitability at low concentrations [18], despite this effect upon 
GABAA receptor at higher concentrations. Hence, it can be hypothesized that the potential 
therapeutic effects of (Mo) on the GABAA receptor is dominated by neuronal depression (via 
voltage-dependent sodium channel blockade, demonstrated by previous published 
electrophysiology studies [18,19]). 
 
  
 
 
European Journal of Medicinal Plants, 4(7): 810-818, 2014 
 
 
816 
 
 
 
Treatment (mg/ml) 
 
 
 
Fig. 2. Dose-dependent effects of Melissa oil (Mo) on primary neuronal culture 
viability. Results are mean absorbance ± SEM for n = 6 individual replicates. Mild 
toxicity at high concentrations with low affinity to GABAA receptor inhibitory 
properties/ modest protection at 0.001 mg/ml 
 
4. CONCLUSION 
 
The present study has identified one compound (trans-ocimene) which likely represents the 
GABAA receptor inhibitory component previously identified in Mo and La. Therefore, the 
results of this study provided a better understanding of the pharmacology of the Melissa 
essential oil and its constituents related to BPSD and in other central nervous system 
disorders such as refractory epilepsy and chronic pain states.  
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